ストックスクリーナーアプリを入手
4.59
0.33%
0.015
アフターアワーズ：
4.65
0.06
+1.31%
前日終値:
$4.575
開ける：
$4.52
24時間の取引高:
2,206
Relative Volume:
0.03
時価総額：
$14.77M
収益：
-
当期純損益:
$-37.68M
株価収益率:
-0.3878
EPS:
-11.8364
ネットキャッシュフロー:
$-30.65M
1週間 パフォーマンス:
+4.32%
1か月 パフォーマンス:
+3.38%
6か月 パフォーマンス:
-47.90%
1年 パフォーマンス:
-39.53%
1日の値動き範囲:
$4.42
$4.67
1週間の範囲:
$4.25
$4.72
52週間の値動き範囲:
$3.29
$20.00
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.59 | 14.77M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-04-21 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-03-31 | 開始されました | Oppenheimer | Outperform |
| 2026-02-10 | 再開されました | Chardan Capital Markets | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
| 2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
| 2021-07-01 | 開始されました | Raymond James | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-03-04 | アップグレード | Goldman | Neutral → Buy |
| 2021-02-04 | 開始されました | Guggenheim | Buy |
| 2021-01-25 | 開始されました | Wedbush | Outperform |
| 2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 開始されました | Citigroup | Neutral |
| 2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2020-03-24 | 開始されました | Cowen | Outperform |
| 2020-03-24 | 開始されました | Goldman | Buy |
| 2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan
Layoff Tracker: MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles - biospace.com
Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60% - Fierce Biotech
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView
PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView
Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView
CYBR.O Forecast — Price Prediction for 2026. Should I Buy CYBR.O? - Intellectia AI
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
PASG Q2'26 Earnings: EPS estimate is (2.65) USD - TradingView
Passage Bio Inc. (PASG) Slips 3% as Shares Approach Key Support LevelMoving Average Ribbon - dars.gov.et
Passage Bio Inc (PASG) Cash Flow - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Balance Sheet - TradingKey
PASG|Passage Bio Inc|Price:4.570|Chg%:-0.370 - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG - TradingView
Passage Bio (PASG) Q1 2026 Earnings: Narrowed Loss Exceeds Expectations Amid Continued Pipeline ProgressProfit Recovery Report - dars.gov.et
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG - Finansavisen
PASG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline in Pre-Revenue PhaseHigh Growth Earnings - dars.gov.et
Passage Bio (PASG) to merge with Remix in $100M-backed oncology deal - Stock Titan
Form 4 Passage Bio Inc For: 22 July By Investing.com - Investing.com Nigeria
PASG: Merger creates a leading RNA-focused biotech with REM-422 poised for ACC and AML impact - TradingView
Passage Bio (NASDAQ: PASG) to merge with Remix Therapeutics in $346M stock deal - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss as Cost Controls SurpriseEarnings Cycle Outlook - dars.gov.et
Passage Bio (PASG) Surges Over 10% – Breaking Resistance Suggests Renewed MomentumDiagonal Spread Trade - po-news-eg.net
Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline - Ad Hoc News
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.3%Post-Earnings Reaction - po-news-eg.net
Passage Bio Inc. (PASG) Rises 7.3% as Momentum Lifts Shares Above Key SupportElliott Wave Count - DonanımHaber
Passage Bio (PASG) Surges 7.3% as Stock Tests Key Resistance at $5.25Sentiment Divergence - DonanımHaber
Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential - ad-hoc-news.de
PASG Q1 2026 Earnings: Narrowed Losses Beat Estimates as Clinical Progress ContinuesNegative Surprise Momentum - dars.gov.et
SPRY, PASG, BOXL: Why these stocks plunged double digits in after-hours trading today - MSN
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus
Passage Bio, Inc. Financial Disclosures & SEC Filings - TradingView
Passage Bio explores gene therapy potential as investors weigh long-term prospects - AD HOC NEWS
Deal Watch: Boehringer Ingelheim Unveils Cancer Pacts With Immunai And Combotope - insights.citeline.com
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):